Molecular markers in the bone marrow micrometastasis of esophageal cancer

doi:10.3760/cma.j.issn.1673-422X.2013.11.012

Abstract

Abstract: In recent years, the bone marrow micrometastasis of esophageal cancer has become the research focus. Many studies show that epithelial cell molecules, angiogenesis markers, chemokine receptor-4 (CXCR-4), HER2, activated leukocyte cell adhesion molecule (ALCAM) and stanniocalcin-1 (STC-1) are closely related to the bone marrow micrometastasis of esophageal cancer. These molecular markers play important roles in esophageal cancer diagnosis, prognosis and treatment.

Key words: Esophageal neoplasms, Neoplasm micrometastasis, Tumor markers, biological

MA Lan, LIU Lian-Ke. Molecular markers in the bone marrow micrometastasis of esophageal cancer[J]. Journal of International Oncology, 2013, 40(11): 839-843.

References

［1］ Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin, 2011, 61(2) :69-90. ［2］ Nieman DR, Peters JH. Treatment strategies for esophageal cancer. Gastroenterol Clin North Am, 2013,42(1):187-197. ［3］ Kutup A, Yekebas EF, Izbicki JR. Current diagnosis and future impact of micrometastases for therapeutic strategies in adenocarcinoma of the esophagus, gastric cardia, and upper gastric third. Recent Results Cancer Res, 2010,182:115-125. ［4］ Zhang X, Chen SB, Chen JX, et al. CK19 mRNA expression in the bone marrow of patients with esophageal squamous cell carcinoma and its clinical significance. Dis Esophagus, 2010,23(5):437-443. ［5］ Makino T, Yamasaki M, Takeno A, et al. Cytokeratins 18 and 8 are poor prognostic markers in patients with squamous cell carcinoma of the oesophagus. Br J Cancer, 2009, 101(8):1298-1306. ［6］ UsnarskaZubkiewicz L, StrutynskaKarpinska M, PodolakDawidziak M, et al. Epithelial bone marrow cells in patients with advanced esophageal squamous cell carcinoma. Neoplasma, 2009,56(3):245-251. ［7］ Zhang QB, Gao YP, He JT, et al. Establishment of a novel human esophageal squamous cell carcinoma cell line(ESC-410) and its partial biological characterization. Dis Esophagus, 2011, 24(2):120-126. ［8］ Bagheri R, Maddah G, Saedi HS, et al. Bone marrow involvement in esophageal cancer patients who underwent surgical resection. Eur J Cardiothorac Surg, 2011,40(2):343-346. ［9］ Vashist YK, Effenberger KE, Vettorazzi E, et al. Disseminated tumor cells in bone marrow and the natural course of resected esophageal cancer. Ann Surg, 2012,255(6):1105-1112. ［10］ Kaifi JT, Yekebas EF, Schurr P, et al. Tumorcell homing to lymph nodes and bone marrow and CXCR4 expression in esophageal cancer. J Natl Cancer Inst, 2005,97(24):1840-1847. ［11］ Schultze A, Ben Batalla I, Riethdorf S, et al. VEGFR-1 expression levels predict occurrence of disseminated tumor cells in the bone marrow of patients with esophageal carcinoma. Clin Exp Metastasis, 2012,29(8):879-887. ［12］ Gray RT, O′Donnell ME, Verghis RM, et al. Bone marrow micrometastases in esophageal carcinoma: a 10-year follow-up study. Dis Esophagus, 2012,25(8):709-715. ［13］ Spence GM, Graham AN, Mulholland K, et al. Bone marrow micrometastases and markers of angiogenesis in esophageal cancer. Ann Thorac Surg, 2004,78(6):1944-1949. ［14］ Tachezy M, Effenberger K, Zander H, et al. ALCAM (CD166) expression and serum levels are markers for poor survival of esophageal cancer patients. Int J Cancer, 2012,131(2):396-405. ［15］ Van de Veire S, Stalmans I, Heindryckx F, et al. Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease. Cell, 2010,141(1):178-190. ［16］ Gros SJ, Graeff H, Drenckhan A, et al. CXCR4/SDF-1α-mediated chemotaxis in an in vivo model of metastatic esophagealcarcinoma. In Vivo, 2012,26(4):711-718. ［17］ Stoecklein NH, Hosch SB, Bezler M, et al. Direct genetic analysis of single disseminated cancer cells for prediction of outcome and therapy selection in esophageal cancer. Cancer Cell, 2008,13(5):441-453. ［18］ Hjortland GO, Meza-Zepeda LA, Beiske K, et al. Genome wide single cell analysis of chemotherapy resistant metastatic cells in a case of gastroesophageal adenocarcinoma. BMC Cancer, 2011,11:455. ［19］ Gros SJ, Kurschat N, Drenckhan A, et al. Involvement of CXCR4 chemokine receptor in metastastic HER2-positive esophageal cancer. PLoS One, 2012,7(10):e47287. ［20］ Weidle UH, Eggle D, Klostermann S, et al. ALCAM/CD166: cancer-related issues. Cancer Genomics Proteomics, 2010,7(5):231-243. ［21］ Shirakawa M, Fujiwara Y, Sugita Y, et al. Assessment of stanniocalcin-1 as a prognostic marker in human esophageal squamous cell carcinoma. Oncol Rep, 2012,27(4):940-946. ［22］ Song H, Xu B, Yi J. Clinical significance of stanniocalcin-1 detected in peripheral blood and bone marrow of esophageal squamous cell carcinoma patients. J Exp Clin Cancer Res, 2012, 31:35.